Efficiency of Menopausal Hormone Therapy in Women with Menopausal Syndrome

Study Objective: to assess the rate of extragenital pathologies in patients with moderate to severe menopausal syndrome (MPS), and the efficiency of menopausal hormone therapy (MHT) with a drug containing 17β-estradiol (estradiol hemihydrate) and didrogesteron.

Study Design: observational clinical study.

Materials and Methods. 166 women with moderate to severe MPS were examined. All patients were prescribed an MHT drug containing an estrogen component (17β-estradiol — estradiol hemihydrate 2.06mg, equivalent to estradiol — 2.0mg) and gestagen component (didrogesteron 10mg), 1 tablet once daily for 6 months. MPS severity was assessed using the menopausal index proposed in 1959 by H. Kupperman et al., as modified by E. V. Uvarova. If the total value of symptoms was 35–58 points, moderate MPS was diagnosed (n = 70; 42.2%); if the value was over 58 points, it was a case of severe MPS (n = 96; 57.8%). Patients’ status dynamics and MPS severity were assessed prior to MHT, and then 1, 3 and 6 months after treatment initiation.

Study Results. It was found out that, among extragenital pathologies in patients with MPS, most frequently registered were chronic upper respiratory tract inflammations (82.0%), endocrine pathologies (61.4%), stage II and III obesity (44.6%). In moderate MPS, one month of therapy resulted in statistically significant reduction in the amended menopausal index (AMI) of approx. 18 points (37.5%), in 3 months, the reduction was by 22 points (45.8%) (p < 0.05), in 6 months — by 34 points (70.8%) (p < 0.05). In severe MPS, one month of therapy resulted in statistically significant reduction in the AMI of approx. 13 points (21.0%) (p > 0.05), in 3 months, the reduction was by 24 points (38.7%) (p < 0.05), in 6 months — by 38 points (61.3%) (p < 0.05). In one month of MHT, all patients did not have any complaints of flushes.

Conclusion. The rate of extragenital pathologies in women with MPS was high. Once somatic diseases were eliminated, patients demonstrated high therapeutic efficiency of the two-phase drug containing estradiol hemihydrate and didrogesteron in relief of neurovegetative and psychoemotional disorders in menopausal syndrome.

Contribution: Vinokurova, E.A. — study design, review of critically important material, approval of the manuscript for publication, patient examination and treatment, thematic publications reviewing; Gorodnicheva, I.E. — collection of clinical materials, data analysis and interpretation; Kiseleva, M.A. — thematic publications reviewing, statistical data processing, manuscript preparation.

Conflict of interest: The authors declare that they do not have any conflict of interests.

Received: 27.12.2019
Accepted: 21.01.2020